|
1
|
Rasmussen F: Metastatic renal cell cancer.
Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Cowan NC, Hanbury DC, Hora M,
Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC;
European Association of Urology Guideline Group. EAU guidelines on
renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saxena S, Jónsson ZO and Dutta A: Small
RNAs with imperfect match to endogenous mRNA repress translation.
Implications for off-target activity of small inhibitory RNA in
mammalian cells. J Biol Chem. 278:44312–44319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jia LF, Wei SB, Gong K, Gan YH and Yu GY:
Prognostic implications of micoRNA miR-195 expression in human
tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deng H, Guo Y, Song H, Xiao B, Sun W, Liu
Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378
mediate tumor growth suppression by epigenetical regulation in
gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heneghan HM, Miller N, Kelly R, Newell J
and Kerin MJ: Systemic miRNA-195 differentiates breast cancer from
other malignancies and is a potential biomarker for detecting
noninvasive and early stage disease. Oncologist. 15:673–682. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim YW, Kim EY, Jeon D, Liu JL, Kim HS,
Choi JW and Ahn WS: Differential microRNA expression signatures and
cell type-specific association with Taxol resistance in ovarian
cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI
|
|
9
|
Slaby O, Redova M, Poprach A, Nekvindova
J, Iliev R, Radova L, Lakomy R, Svoboda M and Vyzula R:
Identification of MicroRNAs associated with early relapse after
nephrectomy in renal cell carcinoma patients. Genes Chromosomes
Cancer. 51:707–716. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hardwick JM and Soane L: Multiple
functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol.
5:a0087222013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davids MS and Letai A: Targeting the
B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol.
30:3127–3135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Antonsson B: Bax and other pro-apoptotic
Bcl-2 family ‘killer-proteins’ and their victim the mitochondrion.
Cell Tissue Res. 306:347–361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li CL, Chang L, Guo L, Zhao D, Liu HB,
Wang QS, Zhang P, Du WZ, Liu X, Zhang HT, et al: β-elemene induces
caspase-dependent apoptosis in human glioma cells in vitro through
the upregulation of Bax and Fas/FasL and downregulation of Bcl-2.
Asian Pac J Cancer Prev. 15:10407–10412. 2014. View Article : Google Scholar
|
|
15
|
Zhang W, Ha M, Gong Y, Xu Y, Dong N and
Yuan Y: Allicin induces apoptosis in gastric cancer cells through
activation of both extrinsic and intrinsic pathways. Oncol Rep.
24:1585–1592. 2010.PubMed/NCBI
|
|
16
|
Lang SA, Schachtschneider P, Moser C, Mori
A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK and
Stoeltzing O: Dual targeting of Raf and VEGF receptor 2 reduces
growth and metastasis of pancreatic cancer through direct effects
on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther.
7:3509–3518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ,
Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA
upregulates FLJ10540 and modulates migration and invasion of lung
cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pal HC1, Sharma S, Strickland LR, Agarwal
J, Athar M, Elmets CA and Afaq F: Delphinidin reduces cell
proliferation and induces apoptosis of non-small-cell lung cancer
cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One.
8:e772702013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida
N and Shibuya M: Essential role of Flk-1 (VEGF receptor 2) tyrosine
residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA.
102:1076–1081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fontanella C, Ongaro E, Bolzonello S,
Guardascione M, Fasola G and Aprile G: Clinical advances in the
development of novel VEGFR2 inhibitors. Ann Transl Med.
2:1232014.
|
|
21
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar
|
|
22
|
Conti A, Santoni M, Amantini C, Burattini
L, Berardi R, Santoni G, Cascinu S and Muzzonigro G: Progress of
molecular targeted therapies for advanced renal cell carcinoma.
BioMed Res Int. 2013:4191762013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Troppmair J and Rapp UR: Raf and the road
to cell survival: A tale of bad spells, ring bearers and detours.
Biochem Pharmacol. 66:1341–1345. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stadler WM: Targeted agents for the
treatment of advanced renal cell carcinoma. Cancer. 104:2323–2333.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sridhar SS, Hedley D and Siu LL: Raf
kinase as a target for anticancer therapeutics. Mol Cancer Ther.
4:677–685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chan CH, Jo U, Kohrman A, Rezaeian AH,
Chou PC, Logothetis C and Lin HK: Posttranslational regulation of
Akt in human cancer. Cell Biosci. 4:592014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaul YD and Seger R: The MEK/ERK cascade:
From signaling specificity to diverse functions. Biochim Biophys
Acta. 1773:1213–1226. 2007. View Article : Google Scholar
|
|
28
|
Walker C: Molecular genetics of renal
carcinogenesis. Toxicol Pathol. 26:113–120. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bussolati B, Satolli MA and Camussi G: The
role of angiogenesis in renal carcinoma. G Ital Nefrol. 25:297–305.
2008.(In Italian). PubMed/NCBI
|
|
30
|
Redova M, Svoboda M and Slaby O: MicroRNAs
and their target gene networks in renal cell carcinoma. Biochem
Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma L and Qu L: The function of microRNAs
in renal development and pathophysiology. J Genet Genomics.
40:143–152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar :
|
|
34
|
Kim WY and Kaelin WG Jr: Molecular
pathways in renal cell carcinoma - rationale for targeted
treatment. Semin Oncol. 33:588–595. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reuter CW, Morgan MA, Grünwald V, Herrmann
TR, Burchardt M and Ganser A: Targeting vascular endothelial growth
factor (VEGF)-receptor-signaling in renal cell carcinoma. World J
Urol. 25:59–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rini BI and Rathmell WK: Biological
aspects and binding strategies of vascular endothelial growth
factor in renal cell carcinoma. Clin Cancer Res. 13:741s–746s.
2007. View Article : Google Scholar : PubMed/NCBI
|
